表皮生长因子受体基因外显子19突变肺癌患者血清蛋白质组学分析  

Comparative proteomic analysis of serums from lung cancer patients with epithelial growth factor receptor extron 19-mutation

作　　者：马秋平[1] 赵卉[1] 王威[1] 侯继锋[1] 

机构地区：[1]中国药品生物制品检定所,北京100050

出　　处：《药物分析杂志》2010年第6期1030-1034,共5页Chinese Journal of Pharmaceutical Analysis

摘　　要：目的:为了筛选表皮生长因子受体(EGFR)基因突变的肺癌患者,便于开展针对性的分子靶向治疗,寻找EGFR基因外显子19缺失突变的肺癌患者血清中的标志蛋白。方法:用双向电泳方法比较了12份EGFR基因突变肺癌患者样本(试验组)与12份正常人血清样本(对照组)蛋白谱的异同,对差异点进行质谱鉴定。结果:对照组样本的2-DE图谱出现蛋白斑点(330±28)个,试验组样本出现蛋白斑点(324±22)个;不同人份样本2-DE图谱的主要斑点的位置与数量基本一致,也存在少量个体差异;排除个体差异后,发现试验组样本图谱中1个蛋白点灰度值显著上调。以capillary-LC/Q-TOF-ULTIMA对差异蛋白斑点进行质谱分析的结果显示,灰度值出现上调的蛋白斑点为结合珠蛋白关联蛋白前体与结合珠蛋白前体的混合物。结论:血清中结合珠蛋白的升高可能作为区分EGFR外显子19突变的肺癌与一般的非小细胞肺癌的标志物。Objective：The objective in this study is search for novel serum markers to screen lung cancer patients with epithelial growth factor receptor（EGFR）mutation for molecular targeted therapy.Method：The proteomic difference between the serums from12 lung cancer patients with EGFR extron 19-mutation（experimental group）and the serums from 12 normal persons（control group）was compared by 2-DE method.The differently expressed protein spots were identified by mass spectrum.Results：The total of 330±28 spots in control group samples and 324±22 spots in experimental group samples were obtained by 2-DE.The number and locations of most spots in the gels have no significant difference between the two groups.After excluding the individual differences,a protein spot that was markedly upregulated in experimental group samples was found.Then the spot was identified by capillary-LC/Q-TOF-ULTIMA as haptoglobin precursor and haptoglobin related protein precursor.Conclusion：The results suggested that the increase in haptoglobin level in serum may serve as a molecular marker for lung cancer patients with EGFR extron 19-mutation.

关 键 词：蛋白质组 双向电泳 肺癌 血清 结合珠蛋白 

分 类 号：R917[医药卫生—药物分析学]